It's World FSHD Day and @FSHDSociety has launched Project Mercury. This initiative is aimed at speeding the development of therapies to those affected by FSHD globally. Thanks for inviting our founder, @ChipYVR to share his #FSHD story.

Today we announced our latest investment in @EpicBiotech. Epic's unique approach to correct the molecular pathology implicated in FSHD should lead to an effective treatment that prevents further muscle degeneration and thereby slows disease progression.

Today we announced our investment in Vita Therapeutics. This partnership will support Vita's cell therapy approach, which will stimulate muscle regeneration and help people build up muscle faster than it breaks down. Read more on our website.

We are excited to support @mireculeinc and to be part of this unique and cutting edge approach to a disease-modifying therapy for FSHD. Learn more about miRecule's goals in identifying a muscle-specific antibody conjugated DUX4 inhibitor for FSHD.

We're excited to announce our partnership with Altay Therapeutics, which will help accelerate the discovery and development of much-needed therapies for FSHD. Read the press release and learn more on our website:

We're committing $1M to @n_lorem to gain further insight into the molecular mechanisms that lead to FSHD2. The partnership will support research efforts to inform a therapeutic strategy for this complex disease. Read more about their pioneering work:

Photos by: @erocdavis | Veto Studios.

Our mission-driven organization #SolveFSHD officially launched yesterday & Founder @ChipYVR shared his vision to find a cure to stop muscle degeneration & increase muscle regeneration to improve the healthspan of those living with #FSHD & longevity for all

Chip Wilson, Lululemon founder, announced today he has committed $100M & created a new venture, @SOLVEFSHD with the objective to accelerate finding a cure for facioscapulohumeral muscular dystrophy (#FSHD) by 2027. Chip was diagnosed with #FSHD2 at age 32.